Sarepta Therapeutics Inc (NASDAQ: SRPT) has a price-to-earnings ratio that is above its average at 95.07x. The stock has a 36-month beta value of 0.75. Opinions on the stock are mixed, with 12 analysts rating it as a “buy,” 9 as “overweight,” 0 as “hold,” and 1 as “sell.”
The public float for SRPT is 89.56M, and at present, short sellers hold a 5.56% of that float. On January 31, 2025, the average trading volume of SRPT was 980.00K shares.
SRPT) stock’s latest price update
Sarepta Therapeutics Inc (NASDAQ: SRPT)’s stock price has decreased by -0.87 compared to its previous closing price of 115.45. However, the company has seen a -3.94% decrease in its stock price over the last five trading sessions. businesswire.com reported 2025-01-27 that CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced positive topline results from Part 2 of EMBARK (Study SRP-9001-301), a global, randomized, double-blind, placebo-controlled, Phase 3 clinical study of ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy. Crossover-treated patients, those who received a placebo in Part 1 and.
SRPT’s Market Performance
Sarepta Therapeutics Inc (SRPT) has seen a -3.94% fall in stock performance for the week, with a -5.80% decline in the past month and a -12.14% plunge in the past quarter. The volatility ratio for the week is 2.57%, and the volatility levels for the past 30 days are at 3.57% for SRPT. The simple moving average for the last 20 days is -4.62% for SRPT stock, with a simple moving average of -11.28% for the last 200 days.
Analysts’ Opinion of SRPT
Many brokerage firms have already submitted their reports for SRPT stocks, with Needham repeating the rating for SRPT by listing it as a “Buy.” The predicted price for SRPT in the upcoming period, according to Needham is $202 based on the research report published on November 27, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see SRPT reach a price target of $80. The rating they have provided for SRPT stocks is “Sell” according to the report published on November 25th, 2024.
Cantor Fitzgerald gave a rating of “Overweight” to SRPT, setting the target price at $167 in the report published on November 07th of the previous year.
SRPT Trading at -5.44% from the 50-Day Moving Average
After a stumble in the market that brought SRPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.94% of loss for the given period.
Volatility was left at 3.57%, however, over the last 30 days, the volatility rate increased by 2.57%, as shares sank -5.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.89% upper at present.
During the last 5 trading sessions, SRPT fell by -3.94%, which changed the moving average for the period of 200-days by -6.85% in comparison to the 20-day moving average, which settled at $119.99. In addition, Sarepta Therapeutics Inc saw -5.87% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SRPT starting from Wigzell Hans Lennart Rudolf, who sale 10,500 shares at the price of $124.84 back on Dec 12 ’24. After this action, Wigzell Hans Lennart Rudolf now owns 22,840 shares of Sarepta Therapeutics Inc, valued at $1,310,820 using the latest closing price.
Wigzell Hans Lennart Rudolf, the Director of Sarepta Therapeutics Inc, proposed sale 10,500 shares at $124.80 during a trade that took place back on Dec 12 ’24, which means that Wigzell Hans Lennart Rudolf is holding shares at $1,310,400 based on the most recent closing price.
Stock Fundamentals for SRPT
Current profitability levels for the company are sitting at:
- 0.05 for the present operating margin
- 0.85 for the gross margin
The net margin for Sarepta Therapeutics Inc stands at 0.07. The total capital return value is set at 0.03. Equity return is now at value 12.27, with 3.63 for asset returns.
Based on Sarepta Therapeutics Inc (SRPT), the company’s capital structure generated 0.53 points at debt to capital in total, while cash flow to debt ratio is standing at -0.25. The debt to equity ratio resting at 1.14. The interest coverage ratio of the stock is 4.23.
Currently, EBITDA for the company is -439.2 million with net debt to EBITDA at 6.67. When we switch over and look at the enterprise to sales, we see a ratio of 7.4. The receivables turnover for the company is 3.18for trailing twelve months and the total asset turnover is 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.84.
Conclusion
To sum up, Sarepta Therapeutics Inc (SRPT) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
